USD 90.8
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| GMED | 0.4 | 2.4 | 8.8 | 22.8 | 24.7 | 65.3 | 28.3 | 70.4 | 276.8 | 572.6 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | GMED |
| name | Globus Medical, Inc. |
| price | 90.8 |
| changes percentage | 0.3648 |
| change | 0.33 |
| day low | 89.3375 |
| day high | 91.039 |
| year high | 91.44 |
| year low | 49.33 |
| market cap | 12363994654 |
| price avg 50 | 83.43 |
| price avg 200 | 70.69155 |
| exchange | NYSE |
| volume | 1721320 |
| avg volume | 1008027 |
| open | 90.62 |
| previous close | 90.47 |
| eps | 0.62 |
| pe | 146.45 |
| earnings announcement | 2025-02-20T21:00:00.000+0000 |
| shares outstanding | 136167342 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001237831 | |||
| revenue | 1568476000 | 1022843000 | 53.34 |
| gross profit | 1020302000 | 759118000 | 34.41 |
| gross profit ratio | 0.65 | 0.74 | -12.35 |
| research and development expenses | 124010000 | 73015000 | 69.84 |
| operating expenses | 887160000 | 522867000 | 69.67 |
| interest income | 0 | 14233000 | -100.00 |
| interest expense | 0 | 14233000 | -100.00 |
| ebitda | 346583000 | 304503000 | 13.82 |
| ebitdaratio | 0.22 | 0.31 | -27.98 |
| operating income | 133142000 | 227951000 | -41.59 |
| operating income ratio | 0.08 | 0.22 | -61.91 |
| net income | 122873000 | 190169000 | -35.39 |
| net income ratio | 0.08 | 0.19 | -57.86 |
| eps | 1.09 | 1.89 | -42.33 |
Revenue Growth: revenue increased to 1,568 million in 2023 from 1,023 million in 2022 representing a change of 53.34%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 1,020 million in 2023 from 759 million in 2022 representing a change of 34.41%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 347 million in 2023 from 305 million in 2022 representing a change of 13.82%. The increase in EBITDA indicates improved operational efficiency and profitability.
Research and Development (R&D) Expenses: R&D Expenses decreased to 124 million in 2023 from 73 million in 2022 representing a change of 69.84%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 887 million in 2023 from 523 million in 2022 representing a change of 69.67%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to 133 million in 2023 from 228 million in 2022 representing a change of -41.59%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 123 million in 2023 from 190 million in 2022 representing a change of -35.39%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 1.09 in 2023 from 1.09 in 2022 representing a change of -42.33%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001237831 | |||
| revenue | 625705000 | 629691000 | -0.63 |
| gross profit | 325114000 | 339942000 | -4.36 |
| gross profit ratio | 0.52 | 0.54 | -3.75 |
| research and development expenses | 35380000 | 37698000 | -6.15 |
| operating expenses | 276118000 | 275817000 | 0.11 |
| interest income | 0 | 0 | NaN |
| interest expense | 775000 | 2335000 | -66.81 |
| ebitda | 115943000 | 113505000 | 2.15 |
| ebitdaratio | 0.19 | 0.2 | -8.64 |
| operating income | 48098000 | 64125000 | -24.99 |
| operating income ratio | 0.08 | 0.1 | -24.52 |
| net income | 51836000 | 31760000 | 63.21 |
| net income ratio | 0.08 | 0.05 | 64.25 |
| eps | 0.38 | 0.23 | 65.22 |
Revenue Growth: revenue decreased to 626 million in 2024Q3 from 630 million in 2024Q2 representing a change of -0.63%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 325 million in 2024Q3 from 340 million in 2024Q2 representing a change of -4.36%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 35 million in 2024Q3 from 38 million in 2024Q2 representing a change of -6.15%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 276 million in 2024Q3 from 276 million in 2024Q2 representing a change of 0.11%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to 48 million in 2024Q3 from 64 million in 2024Q2 representing a change of -24.99%. The decrease in operating income indicates worse operational performance and decreased profitability.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 116 million in 2024Q3 from 114 million in 2024Q2 representing a change of 2.15%. The increase in EBITDA indicates improved operational efficiency and profitability.
Net Income: Net income increased to 52 million in 2024Q3 from 32 million in 2024Q2 representing a change of 63.21%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.38 in 2024Q3 from 0.38 in 2024Q2 representing a change of 65.22%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001237831 | |||
| total assets | 5086083000 | 2076126000 | 144.98 |
| total liabilities | 1088124000 | 229753000 | 373.61 |
| total equity | 3997959000 | 1846373000 | 116.53 |
| cash and cash equivalents | 467292000 | 150466000 | 210.56 |
| short term investments | 50497000 | 295592000 | -82.92 |
| long term investments | 75428000 | 495852000 | -84.79 |
| total current assets | 1915374000 | 983344000 | 94.78 |
| total non current assets | 3170709000 | 1092782000 | 190.15 |
| total current liabilities | 392347000 | 159204000 | 146.44 |
| total non current liabilities | 695777000 | 70549000 | 886.23 |
| common stock | 136000 | 100000 | 36.00 |
| retained earnings | 1137266000 | 1239951000 | -8.28 |
| total debt | 520404000 | 6011000 | 8557.53 |
Total Assets: Total Assets increased to 5,086 million in 2023 from 2,076 million in 2022 representing a change of 144.98%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 3,998 million in 2023 from 1,846 million in 2022 representing a change of 116.53%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 467 million in 2023 from 150 million in 2022 representing a change of 210.56%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 1,915 million in 2023 from 983 million in 2022 representing a change of 94.78%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 36.0%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 1,088 million in 2023 from 230 million in 2022 representing a change of 373.61%. This indicates an increase in overall liabilities.
Short Term Investments: Short Term Investments decreased to 50 million in 2023 from 296 million in 2022 representing a change of -82.92%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 392 million in 2023 from 159 million in 2022 representing a change of 146.44%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to 1,137 million in 2023 from 1,240 million in 2022 representing a change of -8.28%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 520 million in 2023 from 6 million in 2022 representing a change of 8557.53%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001237831 | |||
| total assets | 5086044000 | 4993793000 | 1.85 |
| total liabilities | 1016647000 | 1017428000 | -0.08 |
| total equity | 4069397000 | 3976365000 | 2.34 |
| cash and cash equivalents | 622766000 | 410424000 | 51.74 |
| short term investments | 71940000 | 82509000 | -12.81 |
| long term investments | 12297000 | 27795000 | -55.76 |
| total current assets | 2056529000 | 1923891000 | 6.89 |
| total non current assets | 3029515000 | 3069901999 | -1.32 |
| total current liabilities | 818065000 | 794146000 | 3.01 |
| total non current liabilities | 198582000 | 223282000 | -11.06 |
| common stock | 135000 | 135000 | 0.00 |
| retained earnings | 1126308000 | 1074472000 | 4.82 |
| total debt | 534558000 | 531027000 | 0.66 |
Total Assets: Total Assets increased to 5,086 million in 2024Q3 from 4,994 million in 2024Q2 representing a change of 1.85%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 1,017 million in 2024Q3 from 1,017 million in 2024Q2 representing a change of -0.08%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 4,069 million in 2024Q3 from 3,976 million in 2024Q2 representing a change of 2.34%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 623 million in 2024Q3 from 410 million in 2024Q2 representing a change of 51.74%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 2,057 million in 2024Q3 from 1,924 million in 2024Q2 representing a change of 6.89%. This indicates a better liquidity position.
Retained Earnings: Retained Earnings increased to 1,126 million in 2024Q3 from 1,074 million in 2024Q2 representing a change of 4.82%. This indicates an accumulated profits.
Short Term Investments: Short Term Investments decreased to 72 million in 2024Q3 from 83 million in 2024Q2 representing a change of -12.81%. This indicates a decrease in short-term investment holdings.
Total Current Liabilities: Total Current Liabilities increased to 818 million in 2024Q3 from 794 million in 2024Q2 representing a change of 3.01%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 535 million in 2024Q3 from 531 million in 2024Q2 representing a change of 0.66%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001237831 | |||
| net change in cash | 316826000 | -42603000 | 843.67 |
| operating cash flow | 243499000 | 178468000 | 36.44 |
| free cash flow | 165225000 | 104421000 | 58.23 |
| capital expenditure | -78274000 | -74047000 | -5.71 |
| depreciation and amortization | 144733000 | 68252000 | 112.06 |
| deferred income tax | -57789000 | -22223000 | -160.04 |
| stock based compensation | 52742000 | 32810000 | 60.75 |
| accounts payables | -14223000 | 14418000 | -198.65 |
| inventory | -70328000 | -61745000 | -13.90 |
| acquisitions net | -296028000 | -31435000 | -841.71 |
| investments in property plant and equipment | -78274000 | -74047000 | -5.71 |
| net cash used for investing activites | 302968000 | -110362000 | 374.52 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | -225562000 | -144493000 | -56.11 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -231821000 | -109962000 | -110.82 |
| cash at end of period | 467292000 | 150466000 | 210.56 |
| accounts receivables | -49914000 | -50843000 | 1.83 |
| cash at beginning of period | 150466000 | 193069000 | -22.07 |
Net Change in Cash: Net Change in Cash increased to 317 million in 2023 from -43 million in 2022 representing a change of 843.67%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 243 million in 2023 from 178 million in 2022 representing a change of 36.44%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 165 million in 2023 from 104 million in 2022 representing a change of 58.23%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -78 million in 2023 from -74 million in 2022 representing a change of -5.71%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 14 million in 2023 from 14 million in 2022 representing a change of -198.65%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Stock-Based Compensation: Stock-Based Compensation increased to 53 million in 2023 from 33 million in 2022 representing a change of 60.75%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to -50 in 2023 from -51 million in 2022 representing a change of 1.83%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001237831 | |||
| operating cash flow | 203654000 | 54258000 | 275.34 |
| free cash flow | 161702000 | 26460000 | 511.12 |
| capital expenditure | -41952000 | -27798000 | -50.92 |
| depreciation and amortization | 66947000 | 63589000 | 5.28 |
| deferred income tax | -27448000 | -20184000 | -35.99 |
| stock based compensation | 12211000 | 12813000 | -4.70 |
| accounts receivables | 23661000 | -87813000 | 126.94 |
| accounts payables | -10267000 | 17314000 | -159.30 |
| inventory | 4882000 | -13869000 | 135.20 |
| acquisitions net | 26143000 | -4886000 | 635.06 |
| investments in property plant and equipment | -41952000 | -27798000 | -50.92 |
| net cash used for investing activites | -14967000 | -10378000 | -44.22 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 23505000 | 0 | NaN |
| common stock repurchased | 0 | -1471000 | 100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 19583000 | 8709000 | 124.86 |
| net change in cash | 212342000 | 56362000 | 276.75 |
| cash at end of period | 622766000 | 410424000 | 51.74 |
| cash at beginning of period | 410424000 | 354062000 | 15.92 |
Net Change in Cash: Net Change in Cash increased to 212 million in 2024Q3 from 56 million in 2024Q2 representing a change of 276.75%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 204 million in 2024Q3 from 54 million in 2024Q2 representing a change of 275.34%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 162 million in 2024Q3 from 26 million in 2024Q2 representing a change of 511.12%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -42 million in 2024Q3 from -28 million in 2024Q2 representing a change of -50.92%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 12 million in 2024Q3 from 13 million in 2024Q2 representing a change of -4.7%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 10 million in 2024Q3 from 17 million in 2024Q2 representing a change of -159.3%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 24 in 2024Q3 from -88 million in 2024Q2 representing a change of 126.94%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 13.87 | 10.18 | 36.23 |
| net income per share | 1.09 | 1.89 | -42.60 |
| operating cash flow per share | 2.15 | 1.78 | 21.21 |
| free cash flow per share | 1.46 | 1.04 | 40.57 |
| cash per share | 4.58 | 4.44 | 3.13 |
| book value per share | 35.35 | 18.38 | 92.37 |
| tangible book value per share | 14.49 | 15.78 | -8.16 |
| shareholders equity per share | 35.35 | 18.38 | 92.37 |
| interest debt per share | 4.6 | 0.2 | 2183.83 |
| market cap | 6026406230 | 7461832630 | -19.24 |
| enterprise value | 6079518230 | 7317377630 | -16.92 |
| pe ratio | 49.05 | 39.24 | 25.00 |
| price to sales ratio | 3.84 | 7.3 | -47.33 |
| pocfratio | 24.75 | 41.81 | -40.81 |
| pfcf ratio | 36.47 | 71.46 | -48.96 |
| pb ratio | 1.51 | 4.04 | -62.70 |
| ptb ratio | 1.51 | 4.04 | -62.70 |
| ev to sales | 3.88 | 7.15 | -45.82 |
| enterprise value over ebitda | 17.54 | 24.03 | -27.00 |
| ev to operating cash flow | 24.97 | 41.0 | -39.11 |
| ev to free cash flow | 36.8 | 70.08 | -47.49 |
| earnings yield | 0.02 | 0.03 | -20.00 |
| free cash flow yield | 0.03 | 0.01 | 95.92 |
| debt to equity | 0.13 | 0.0 | 3898.30 |
| debt to assets | 0.1 | 0.0 | 3433.98 |
| net debt to ebitda | 0.15 | -0.47 | 132.30 |
| current ratio | 4.88 | 6.18 | -20.96 |
| interest coverage | 0 | 16.02 | -100.00 |
| income quality | 1.98 | 0.94 | 111.16 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.08 | 0.07 | 10.76 |
| intangibles to total assets | 0.46 | 0.13 | 268.90 |
| capex to operating cash flow | 0.32 | 0.41 | -22.52 |
| capex to revenue | 0.05 | 0.07 | -31.06 |
| capex to depreciation | 0.54 | 1.08 | -50.15 |
| stock based compensation to revenue | 0.03 | 0.03 | 4.83 |
| graham number | 29.4 | 27.98 | 5.08 |
| roic | 0.02 | 0.09 | -77.38 |
| return on tangible assets | 0.05 | 0.1 | -56.99 |
| graham net net | 2.05 | 5.26 | -60.96 |
| working capital | 1523027000 | 824140000 | 84.80 |
| tangible asset value | 1638816000 | 1585328000 | 3.37 |
| net current asset value | 827250000 | 753591000 | 9.77 |
| invested capital | 4529033000 | 1328914000 | 240.81 |
| average receivables | 361089000 | 191479500 | 88.58 |
| average payables | 46386000 | 29028000 | 59.80 |
| average inventory | 573558000 | 267991000 | 114.02 |
| days sales outstanding | 117.49 | 77.55 | 51.51 |
| days payables outstanding | 37.73 | 49.96 | -24.48 |
| days of inventory on hand | 564.73 | 413.79 | 36.48 |
| receivables turnover | 3.11 | 4.71 | -34.00 |
| payables turnover | 9.67 | 7.31 | 32.41 |
| inventory turnover | 0.65 | 0.88 | -26.73 |
| roe | 0.03 | 0.1 | -70.16 |
| capex per share | 0.69 | 0.74 | -6.09 |
ROE: Return on Equity (ROE) decreased to 0.03 on 2023-12-31 from 0.10 on 2022-12-31, representing a change of -70.16%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 4.88 on 2023-12-31 from 6.18 on 2022-12-31, representing a change of -20.96%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 49.05 on 2023-12-31 from 39.24 on 2022-12-31, representing a change of 25.00%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.13 on 2023-12-31 from 0.00 on 2022-12-31, representing a change of 3898.30%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| GMED | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 4.61 | 4.66 | -0.94 |
| net income per share | 0.38 | 0.23 | 62.71 |
| operating cash flow per share | 1.5 | 0.4 | 274.18 |
| free cash flow per share | 1.19 | 0.2 | 509.23 |
| cash per share | 5.12 | 3.65 | 40.50 |
| book value per share | 30.01 | 29.41 | 2.02 |
| tangible book value per share | 13.24 | 12.25 | 8.08 |
| shareholders equity per share | 30.01 | 29.41 | 2.02 |
| interest debt per share | 3.95 | 3.95 | 0.06 |
| market cap | 9701897100 | 9182444400 | 5.66 |
| enterprise value | 9613689100 | 9303047400 | 3.34 |
| pe ratio | 46.79 | 72.28 | -35.26 |
| price to sales ratio | 15.51 | 14.58 | 6.33 |
| pocfratio | 47.64 | 169.24 | -71.85 |
| pfcf ratio | 60.0 | 347.03 | -82.71 |
| pb ratio | 2.38 | 2.31 | 3.24 |
| ptb ratio | 2.38 | 2.31 | 3.24 |
| ev to sales | 15.36 | 14.77 | 4.00 |
| enterprise value over ebitda | 82.92 | 81.96 | 1.17 |
| ev to operating cash flow | 47.21 | 171.46 | -72.47 |
| ev to free cash flow | 59.45 | 351.59 | -83.09 |
| earnings yield | 0.01 | 0.0 | 54.47 |
| free cash flow yield | 0.02 | 0.0 | 478.40 |
| debt to equity | 0.13 | 0.13 | -1.64 |
| debt to assets | 0.11 | 0.11 | -1.16 |
| net debt to ebitda | -0.76 | 1.06 | -171.60 |
| current ratio | 2.51 | 2.42 | 3.77 |
| interest coverage | 62.06 | 27.46 | 125.99 |
| income quality | 3.93 | 1.71 | 129.97 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.06 | 0.06 | -5.55 |
| intangibles to total assets | 0.45 | 0.46 | -3.77 |
| capex to operating cash flow | 0.21 | 0.51 | -59.79 |
| capex to revenue | 0.07 | 0.04 | 51.88 |
| capex to depreciation | 0.63 | 0.44 | 43.35 |
| stock based compensation to revenue | 0.02 | 0.02 | -4.09 |
| graham number | 16.06 | 12.47 | 28.84 |
| roic | 0.01 | 0.01 | 0.53 |
| return on tangible assets | 0.02 | 0.01 | 55.17 |
| graham net net | 3.52 | 2.38 | 48.22 |
| working capital | 1238464000 | 1129745000 | 9.62 |
| tangible asset value | 1794953000 | 1655683000 | 8.41 |
| net current asset value | 1039882000 | 906463000 | 14.72 |
| invested capital | 4133554000 | 4077744000 | 1.37 |
| average receivables | 601164500 | 574490499.5 | 4.64 |
| average payables | 62350000 | 58825000 | 5.99 |
| average inventory | 744083000 | 793329500 | -6.21 |
| days sales outstanding | 84.58 | 87.8 | -3.66 |
| days payables outstanding | 17.23 | 20.86 | -17.42 |
| days of inventory on hand | 214.89 | 239.32 | -10.21 |
| receivables turnover | 1.06 | 1.03 | 3.80 |
| payables turnover | 5.22 | 4.31 | 21.10 |
| inventory turnover | 0.42 | 0.38 | 11.37 |
| roe | 0.01 | 0.01 | 59.48 |
| capex per share | 0.31 | 0.21 | 50.45 |
ROE: Return on Equity (ROE) decreased to 0.01 on 2024-09-30 Q3 from 0.01 on 2024-06-30 Q2, representing a change of 59.48%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 46.79 on 2024-09-30 Q3 from 72.28 on 2024-06-30 Q2, representing a change of -35.26%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.51 on 2024-09-30 Q3 from 2.42 on 2024-06-30 Q2, representing a change of 3.77%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.13 on 2024-09-30 Q3 from 0.13 on 2024-06-30 Q2, representing a change of -1.64%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 73.16 which is lower than current price 90.8, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-10 11:26:14
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Sentiment: Positive
Publish Date: 2025-01-08 16:30:00
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2024. The company anticipates fourth quarter 2024 sales of approximately $657.0 million, an increase of 6.6 percent over the fourth quarter 2023 on an as-reported basis. Full year 2024 sales are expected to be approximately $2.52 billion, an increase of 60.6 percent over the prior year on an as-reported basis.
Sentiment: Neutral
Publish Date: 2025-01-08 12:10:00
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Continues Its Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors.
Sentiment: Positive
Publish Date: 2025-01-02 11:07:57
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sentiment: Neutral
Publish Date: 2024-12-24 10:11:11
Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport.
Sentiment: Positive
Publish Date: 2024-12-24 08:46:11
Globus Medical's synergistic merger with NuVasive and a strong liquidity position bring optimism to investors.
Sentiment: Neutral
Publish Date: 2024-12-19 13:57:29
The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty.
Sentiment: Neutral
Publish Date: 2024-12-12 03:16:11
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
Sentiment: Positive
Publish Date: 2024-12-11 08:55:37
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
Sentiment: Positive
Publish Date: 2024-12-05 13:01:23
Globus Medical (GMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sentiment: Neutral
Publish Date: 2024-12-05 12:35:53
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?
Sentiment: Positive
Publish Date: 2024-12-02 15:26:19
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Sentiment: Positive
Publish Date: 2024-11-29 13:46:33
Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.
Sentiment: Positive
Publish Date: 2024-11-29 12:46:29
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?
Sentiment: Positive
Publish Date: 2024-11-25 09:25:30
Globus Medical commercially launches ExcelsiusHub navigation system to elevate the standard for freehand navigation.
Sentiment: Positive
Publish Date: 2024-11-22 16:30:00
AUDUBON, Pa., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ExcelsiusHub™ navigation system. ExcelsiusHub™ joins the expansive ecosystem of Excelsius™ technologies and is designed to elevate the standard for freehand navigation.
Sentiment: Positive
Publish Date: 2024-11-22 10:16:08
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Sentiment: Positive
Publish Date: 2024-11-15 10:51:27
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sentiment: Positive
Publish Date: 2024-11-14 10:46:04
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sentiment: Positive
Publish Date: 2024-11-13 13:51:16
Globus Medical (GMED) possesses solid growth attributes, which could help it handily outperform the market.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
